- Home
- OPHC vs SCYX Comparison
OPHC vs SCYX Comparison
Compare OPHC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- SCYX
- Stock Information
- Founded
- OPHC 2000
- SCYX 1999
- Country
- OPHC United States
- SCYX United States
- Employees
- OPHC N/A
- SCYX N/A
- Industry
- OPHC Major Banks
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- SCYX Health Care
- Exchange
- OPHC Nasdaq
- SCYX Nasdaq
- Market Cap
- OPHC 49.0M
- SCYX 40.6M
- IPO Year
- OPHC N/A
- SCYX 2014
- Fundamental
- Price
- OPHC $4.49
- SCYX $1.07
- Analyst Decision
- OPHC Hold
- SCYX Buy
- Analyst Count
- OPHC 1
- SCYX 1
- Target Price
- OPHC $5.25
- SCYX N/A
- AVG Volume (30 Days)
- OPHC 45.7K
- SCYX 164.6K
- Earning Date
- OPHC 02-05-2025
- SCYX 03-27-2025
- Dividend Yield
- OPHC N/A
- SCYX N/A
- EPS Growth
- OPHC 53.23
- SCYX N/A
- EPS
- OPHC 1.33
- SCYX N/A
- Revenue
- OPHC $37,091,000.00
- SCYX $8,566,000.00
- Revenue This Year
- OPHC N/A
- SCYX N/A
- Revenue Next Year
- OPHC N/A
- SCYX $365.06
- P/E Ratio
- OPHC $3.38
- SCYX N/A
- Revenue Growth
- OPHC 60.44
- SCYX N/A
- 52 Week Low
- OPHC $4.00
- SCYX $0.90
- 52 Week High
- OPHC $5.90
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- OPHC 37.59
- SCYX 43.42
- Support Level
- OPHC $4.71
- SCYX $1.06
- Resistance Level
- OPHC $4.80
- SCYX $1.18
- Average True Range (ATR)
- OPHC 0.11
- SCYX 0.07
- MACD
- OPHC -0.01
- SCYX -0.00
- Stochastic Oscillator
- OPHC 0.00
- SCYX 22.22
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.